Primary results from CALIBRATE, the Phase 3 registrational clinical trial of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) on May 12, 2026 at ...

Janus Henderson Group plc (NYSE: JHG; “JHG," "Janus Henderson,” or the “Company”) published its first quarter 2026 results for the period ended March 31, 2026. First quarter 2026 operating income was ...

First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-yearFull year 2026 revenue guidance raised to $72 million to $77 ...

U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentumContinued ...

CHICAGO, May 7, 2026 /PRNewswire/ -- Cars.com Inc. (NYSE: CARS), a trusted audience-powered and data-driven technology ...

Delivered profitable first quarter 2026 results, with net income from continuing operations of $5.1 million, or $0.15 per diluted share, for the first quarter of 2026 compared to $0.7 million, or ...

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...

ACM Research, Inc. ('ACM”) (NASDAQ: ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced ...

Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) - ...

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody fo ...

Detailed price information for Lifecore Biomedical Inc (LFCR-Q) from The Globe and Mail including charting and trades.

Q1 2026 Revenues of $244.7 million grew 5.8% compared to Q1 2025 Net Loss of $73.6 million Adjusted EBITDA of $146.9 million ...